Table 3 Subgroup analyses between alcohol consumption and the risk of H. pylori eradication failure in Asia
From: Alcohol increases treatment failure for Helicobacter pylori eradication in Asian populations
Variable | Number of Data | Odd ratios (95% CI), % | I2 (%) | P-value for heterogeneity | |
|---|---|---|---|---|---|
Duration of therapy | 7 days | 19 | 1.23 (0.94–1.60) | 47.4 | 0.012 |
 > 7 days | 8 | 1.17 (1.01–1.25) | 40.4 | 0.109 | |
Antibiotic types | Clarithromycin | 20 | 1.15 (0.91–1.45) | 41.9 | 0.026 |
Non-Clarithromycin | 8 | 1.18 (1.10–1.26) | 44.5 | 0.082 | |
Nitroimidazoles | 3 | 1.16 (1.09–1.24) | 0.00 | 0.461 | |
Non- Nitroimidazoles | 25 | 1.24 (0.99–1.57) | 46.2 | 0.007 | |
Treatment options | VPZ-based therapy | 5 | 1.73 (0.98–3.05) | 0.00 | 0.897 |
bismuth-containing quadruple therapy | 7 | 1.17 (1.10–1.25) | 40.7 | 0.028 | |
Alcohol consumption |  < 40 g/day | 4 | 1.15 (0.54–2.45) | 59.1 | 0.062 |
 > 40 g/day | 3 | 3.17 (1.56–6.41) | 0.00 | 0.520 | |